Signal transducer and activator of transcription 3 (STAT3) is linked to multiple cancers, including pulmonary adenocarcinoma. However, the role of STAT3 in lung cancer pathogenesis has not been determined. Using lung epithelial-specific inducible knockout strategies, we demonstrate that STAT3 has contrasting roles in the initiation and growth of both chemically and genetically induced lung cancers. Selective deletion of lung epithelial STAT3 in mice before cancer induction by the smoke carcinogen, urethane, resulted in increased lung tissue damage and inflammation, K-Ras oncogenic mutations and tumorigenesis. Deletion of lung epithelial STAT3 after establishment of lung cancer inhibited cancer cell proliferation. Simultaneous deletion of STAT3 and expression of oncogenic K-Ras in mouse lung elevated pulmonary injury, inflammation and tumorigenesis, but reduced tumor growth. These studies indicate that STAT3 prevents lung cancer initiation by maintaining pulmonary homeostasis under oncogenic stress, whereas it facilitates lung cancer progression by promoting cancer cell growth. These studies also provide a mechanistic basis for targeting STAT3 to lung cancer therapy.
INTRODUCTION
Lung cancer is the leading cause of cancer deaths worldwide, with a dismal 16% five-year survival rate. 1 The most predominant risk factor for lung cancer is tobacco smoking, which accounts for about 87% of lung cancer cases. 2 Tobacco smoke causes genetic alterations, particularly activating mutations of the K-Ras oncogene, in lung epithelium that initiates and promotes carcinogenesis. 3, 4 Tobacco smoke also induces lung inflammation and damage, creating a microenvironment that facilitates oncogenic mutations and lung cancer initiation and promotion. 5, 6 Tobacco smoke contains more than 60 chemical carcinogens, and one of the well-defined and most commonly used smoke carcinogens for cancer study is ethyl carbamate, also called urethane. 2 Urethane alone is sufficient to induce K-Ras-activating mutations and lung carcinogenesis in mice. 7 Remarkably, murine lung cancers induced by urethane or directly driven by oncogenic K-Ras faithfully recapitulate human lung cancers, and in particular adenocarcinomas associated with tobacco smoking. 7 They share the same genetic and molecular changes, as well as morphology and histology. Moreover, murine lung cancers induced by urethane or oncogenic K-Ras, like their human counterparts, are associated with pulmonary inflammation. Accordingly, lung carcinogenesis induced by urethane or oncogenic K-Ras in mice has been well accepted and widely used as models for human lung cancers, especially those induced by smoking or associated with K-Ras mutations.
It has been well documented that K-Ras activation and inflammation induce activation of signal transducer and activator of transcription 3 (STAT3), a central regulator of numerous cellular processes, particularly cell proliferation. 8, 9 STAT3 has been proposed as an oncogene, based on experiments showing that a constitutively active form of STAT3 is able to transform fibroblast or epithelia cells in vitro and induce epithelial carcinogenesis in mice. [10] [11] [12] However, naturally occurring activating mutations of STAT3 have not been found. Moreover, both positive and negative associations between STAT3 activation and patient survival or tumor progression have been reported. [13] [14] [15] [16] [17] Most paradoxically, loss-of-function studies indicate that STAT3 may have a positive or negative role in tumorigenesis. [18] [19] [20] [21] [22] [23] Thus, the role of STAT3 in tumorigenesis seems complex and requires a careful and systematic study. This is of importance, because STAT3 is a target of great interest for the prevention and treatment of lung and other cancers. 24 To dissect the role of STAT3 in lung tumorigenesis, we applied a lung epithelial-specific inducible knockout approach in both urethane-and K-Ras-induced murine lung cancer models. We find that lung epithelial STAT3 had distinct and opposing roles in the initiation and growth of lung cancer. Although STAT3 is required for the maximal proliferation/progression of lung cancer cells, lung epithelial STAT3 inhibited pulmonary injury and inflammation under oncogenic stress, suppressing lung cancer initiation. Figure S1 ). These data indicated that lung epithelial STAT3 suppresses tumor initiation in a urethaneinduced lung tumorigenesis model.
RESULTS

Deletion
Increased lung tumorigenesis in urethane-treated STAT3
− / − mice is associated with augmented protumorigenic inflammation Recent studies indicated that pulmonary inflammation plays a critical role in the initiation and progression of lung cancer. 28 To investigate the mechanisms underlying the increased lung tumorigenesis in STAT3 − / − mice treated with urethane, we compared the pulmonary inflammation in STAT3 − / − mice and STAT3 +/+ mice following exposure to urethane. Although the expression levels of the antitumor cytokine interferon-gamma (IFN-γ) were comparable, concentrations of several proinflammatory cytokines known to promote tumor initiation and progression, including tumor necrosis factor-alpha (TNF-α), interleukin1beta (IL-1β) and interleukin 6 (IL-6), were significantly increased in the lungs of urethane-treated STAT3 − / − mice ( Figure 2a ). In addition, the immune cell-attractive chemokine CCL2 was also significantly increased in the lungs of urethane-treated STAT3 Figure S2) . Accordingly, the numbers of inflammatory cells were increased in bronchioalveolar lavage fluid (BALF) from STAT3 − / − mice treated with urethane compared with controls (Figures 2b and c) . Further cell type analysis indicated that lymphocytes, but not neutrophils or macrophages, were significantly increased in the BALF of urethane-treated STAT3 − / − mice (Figures 2b and d) . These data indicated that lung epithelial STAT3 restricts urethane-induced protumorigenic inflammation.
STAT3
− / − mice are more vulnerable to urethane-induced lung damage In association with the increased pulmonary inflammation, STAT3
− / − mice treated with urethane had markedly exacerbated lung injury and edema, compared with controls ( Figure 3 , and Supplementary Figure S3) . Before urethane treatment, the lung morphology and histology of STAT3 − / − mice were not different from controls. 26, 27 Exposure to urethane caused mild alveolar congestion and minor impairments of alveolar epithelial integrity in STAT3 +/+ mice, indicating mild lung injury (Figure 3a i and ii). However, severe lung injury occurred in STAT3 − / − mice exposed to urethane, as evidenced by marked alveolar thickening and congestion, severe loss of the integrity of the bronchiolar and alveolar epithelium, perivascular edema and hemorrhage (Figure 3a iii-vi). Consistently, air space enlargement, red blood cell extravasation and accumulation of extracellular debris and protein were frequently observed in the lungs of urethane-treated STAT3 − / − mice (Figure 3a iii-vi). In further support of these observations, an increased protein concentration was detected in lung lavage fluid (Figure 3b ). These data demonstrated that lung epithelial STAT3 protects lungs from urethane-induced preneoplastic injury and inflammation.
− / − mice are more sensitive to urethane-induced activating mutations of K-Ras One of the important roles of local inflammation and tissue damage is to establish a microenvironment that facilitates induction of oncogenic mutations and subsequent tumor initiation and progression. 5, 26 As activating mutations of the K-Ras oncogene in lung epithelium are an early event involved in urethane-induced lung tumorigenesis in mice, 29, 30 we assessed urethane-induced K-Ras mutations at codon 61, an activating mutation of K-Ras that has also been identified in human lung cancers, in the lungs of urethane-treated WT and STAT3
− / − mice ( Figure 4a ). The mutation rate of K-Ras in the lung type II epithelial cells of STAT3 − / − mice was significantly higher than that in WT mice (Figure 4b ), consistent with the increased incidence of lung cancer in STAT3 − / − mice. Taken together, these data suggested that lung epithelial STAT3 prevents urethane-induced K-Ras oncogenic mutations and lung cancer initiation by maintaining pulmonary homeostasis during urethane-induced injury. Figure S4 ). These data suggested that although STAT3 suppresses lung cancer initiation, it paradoxically contributes to the growth of lung cancer induced by urethane.
To further assess the role of STAT3 in the growth of lung cancers, we conditionally deleted STAT3 after urethane treatment and tumor formation. As shown in Figure 5b and Supplementary Figure S5 , STAT3 was efficiently deleted at both RNA and protein levels from urethane-induced lung tumors in mice after administration of dox. Deletion of STAT3 after tumor formation markedly reduced the size, but had no significant effect on the number of lung tumors (Figures 5c-e), indicating that STAT3 contributes to the growth and progression of lung cancer induced by urethane. BrdU cell proliferation assays showed that STAT3 − / − tumors had much lower proliferation rate than WT tumors (Figure 5f and Supplementary Figure S6 ). Mechanistic studies revealed that compared with STAT3 +/+ tumors, STAT3 − / − tumors expressed significantly lower levels of Cyclin D1, a transcriptional target of STAT3 critical to cell proliferation (Figures 5g and h and Supplementary Figure S7 ). These data suggested that STAT3 is required for the maximal expression of the key cell proliferation regulator Cyclin D1 and the optimal growth and progression of lung cancers induced by urethane.
STAT3 suppresses K-Ras-induced lung tumorigenesis but contributes to the growth of K-Ras mutant lung cancer The loxP-Stop-loxP (LSL) K-Ras G12D genetic model of lung cancer was utilized to further assess the role of STAT3 in K-Ras-mediated pulmonary tumorigenesis. After the mutant K-Ras transgene is activated in lungs by intratracheal administration of adenoviral Cre recombinase (AdenoCre), LSL-K-Ras G12D mice develop lung cancers that closely resemble lung cancer in humans. (Figure 7b ). Moreover, LSL-K-Ras G12D /STAT3 − / − mice showed more severe lung damage, as evidenced by enhanced alveolar thickening and congestion, loss of integrity of the alveolar capillary membrane, air space enlargement, protein leak and red blood cell extravasation in their lungs (Figure 7c , ii-iv versus i). Thus, both the K-Ras-and urethane-induced tumor models demonstrate that STAT3 has distinct and opposing roles in pulmonary tumorigenesis, inhibiting initiation but enhancing growth of lung cancer.
DISCUSSION
Recent clinical studies have shown that STAT3 is activated in human lung cancers and that STAT3 activity is correlated with tumor progression, poor prognosis and short patient survival. [13] [14] [15] Thus, it is of interests and importance to determine whether and how STAT3 is involved in the pathogenesis of lung cancer. These studies will not only greatly improve our understanding of lung cancer but also provide mechanistic insights into the possibility of targeting STAT3 for the treatment of this deadliest type of cancer. The present studies demonstrate, for the first time, that STAT3 has distinct and opposing roles in the initiation as compared with progression of pulmonary adenocarcinomas. The oncogenic role of STAT3 is supported by extensive in vitro, in vivo and clinical evidence. First, constitutive activation of STAT3 has been detected in a large variety of human cancer cell lines and primary tumors, including lung cancer. [13] [14] [15] Second, activation or increased expression of STAT3 has been suggested to be associated with poor patient survival and tumor progression in lung cancer and many other cancer types. [13] [14] [15] Third, several major STAT3 activators, including the v-Src kinase and the IL-6 cytokine, have been shown to promote tumor initiation and progression. 32, 33 Fourth, STAT3 inhibitors, including PDZ-LIM domain-containing protein 2 (PDLIM2), protein tyrosine phosphatase, protein inhibitor of activated STAT3 and suppressor of cytokine signaling 3, exhibit strong tumor suppressive activities. [34] [35] [36] [37] [38] [39] [40] [41] Fifth, inhibition or knockdown of STAT3 suppresses the tumorigenicity of several types of human cancer cell lines. 42, 43 Sixth, cell-specific STAT3-deficient mice are resistant to carcinogenesis, including skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene/12-O-tetradecanoylphorbol-13-acetate, and colon cancer initiation by azoxymethane (AOM)/dextran sulfate sodium or adenomatosis polyposis coli Min mutant (APC min ). [20] [21] [22] Last and most importantly, overexpression of the constitutively active STAT3 transforms fibroblast or epithelial cells in vitro and induces epithelial carcinogenesis in mice. [10] [11] [12] In agreement with the proposed tumor-promoting functions of STAT3, we have found that genetic deletion of STAT3 from endogenous lung cancer cells in mice suppressed the growth of these malignant cells (Figures 5 and 6 ). Strikingly, we have also found that selective deletion of lung epithelial STAT3 increased the incidence of lung cancer induced by the chemical carcinogen urethane or oncogenic K-Ras (Figures 1 and 6 ). These findings suggest that STAT3 has both promoting and suppressing roles in lung tumorigenesis. In line with the tumor suppressive functions of STAT3 in lung tumorigenesis, thyrocyte-specific deletion or inhibition of STAT3 increased thyroid tumorigenesis in a murine model of papillary thyroid carcinoma and tumorigenicity of human thyroid cancer cell lines, respectively. 18 In addition, STAT3 activation in tumors has been reported to be correlated with improved patient survival, small or less aggressive tumors in several cancer types, such as breast cancer, and head and neck squamous cell carcinomas. 16, 17 Present findings demonstrate that both lung tumor-promoting and -suppressing functions of STAT3 involve its ability in promoting cell growth. Whereas STAT3 activates Cyclin D1 that likely promotes lung cancer cell proliferation (Figures 5 and 6 ), STAT3 suppresses lung cancer induction by maintaining lung epithelial homeostasis under inflammatory and oncogenic stress (Figures 2, 3, 6 and 7) . Loss of lung epithelial-specific STAT3 increases urethane-induced lung cell death and exacerbates the severity of lung injury induced by urethane (Figure 3 and Supplementary Figure S3) , which is associated with enhanced pulmonary inflammation, elevated K-Ras oncogenic mutations and increased lung tumor formation (Figures 2 and 4) . Similarly, deletion of STAT3 from lung cells aggravates lung injury, amplifies pulmonary inflammation and augments lung tumorigenesis in mice expressing oncogenic K-Ras in their lungs (Figures 6 and 7) . It seems that lung damage, inflammation, and K-Ras oncogenic activation enhance each other, and function as extrinsic and intrinsic forces to drive lung cancer initiation and progression.
Obviously, it is most likely unfeasible to completely and systematically block STAT3 activation for the therapy of lung cancer or any other types of cancers, given the physiological significance of STAT3 in humans. In this regard, no STAT3 inhibitor has been approved for use in patients, although numerous STAT3 inhibitors have been developed during the past decades. 24 Our studies further suggest that even local inhibition of STAT3 within lungs may be also too toxic, because deletion of lung epithelial STAT3 alone already causes severe pulmonary injury under oncogenic and inflammatory stress (Figures 3 and 7) . In addition, our studies suggest that targeting STAT3 alone is not sufficient for lung cancer therapy, because even genetic deletion of STAT3 cannot completely prevent lung tumorigenesis or induce regression of lung cancers that have already formed (Figures 5 and 6) . Thus, to target STAT3 for cancer therapy, on one hand we need to lower the potential toxicity of STAT3 inhibition, and on the other hand we need to combine STAT3 inhibition with other cancer therapies for efficient clinical outcomes.
In summary, the data presented here demonstrate that lung epithelial STAT3 has distinct and opposing roles in pulmonary tumorigenesis, suppressing initiation but enhancing growth of lung cancer. STAT3 prevents lung cancer initiation through maintaining lung homeostasis and restricting pulmonary inflammation, whereas it contributes to (although it is not absolutely required for) lung cancer growth through inducing expression of key regulators of cell proliferation. These studies not only greatly improve our understanding of the physiologic and pathogenic actions of STAT3 and the pathogenesis of lung cancer, but also provide a mechanistic basis for targeting STAT3 to treat and cure lung cancer. ) control mice were intraperitoneally injected with urethane (1 mg/g body weight) one time per week for 4 weeks. Alternatively, 5-week-old mice were first injected with urethane as the same schedule, and then randomly divided into two groups: one group was administered dox, and the other one was left untreated. Three months post urethane treatment, all mice were killed for lung tumor examinations. 
MATERIALS AND METHODS
Bronchioalveolar lavage (BAL)
Mice were killed, and their lungs were lavaged three times with phosphate-buffered saline. The recovered BAL fluids (BALF) were centrifuged. Cells from BALF were visualized by Hema 3-staining. BALF total cell counts were determined by using a grid hemocytometer, and numbers of different leukocytes were obtained by counting at least 400 cells on Hema 3-stained cytocentrifuge slides. Supernatants of BALF were subjected to the Bicinchoninic Acid protein assay (Thermo Scientific, Rockford, IL, USA) for protein quantitation.
Lung tumor enumeration
Surface tumors in mouse lungs were counted by three blinded readers under a dissecting microscope. Tumor diameters were determined by microcalipers.
Histology and immunohistochemistry
Mouse lungs were excised, fixed in formalin, embedded in paraffin and cut into 4-μm-thick sections. Sections were stained with hematoxylin and eosin or subjected to sequential incubations with different primary antibodies and peroxidase-conjugated goat anti-rabbit or rabbit anti-goat secondary antibodies. The following primary antibodies were used: anti-STAT3 (Cell Signaling, Beverly, MA, USA), anti-Cyclin D1, anti-CCSP and anti-SP-C (Santa Cruz Biotechnology, Dallas, TX, USA).
BrdU labeling
Mice were intraperitoneally injected with 50 mg/kg BrdU (Sigma-Aldrich, St Louis, MO, USA) 24 h before killing. Mouse lung tissue sections were stained with a BrdU in situ detection kit (BD Biosciences, Franklin Lakes, NJ, USA). More than 3000 cells per lung were counted in randomly selected fields. BrdU labeling index was calculated as the percentage of labeled cells per total cells counted as described previously. 44 
Isolation of lung type II epithelial cells
The detailed protocol has been described before. 45, 46 Briefly, crude lung cell suspensions were prepared by intratracheal instillation of Dispase and agarose followed by mechanical disaggregation of the lungs. Crude cell suspensions were purified by negative selection using a biotinylated-antibody, streptavidin-coated biomagnetic particle system. Cell purities were determined by Pap staining and confirmed ultrastructurally. Purified type II cells were cultured on fibronectin-coated chamber slides and maintained for up to 5 days in Dulbecco's Modified Eagle's medium with 10% fetal bovine serum. 
Quantitative polymerase chain reaction (qPCR) analysis
Mouse lung tissues, BAL cells or type II epithelial cells were subjected to RNA extraction, RNA reverse transcription and real-time PCR as described. 47, 48 Genomic DNAs were also extracted from lung type II epithelial cells and used for real-time PCR. Primer pairs used for real-time PCR were: STAT3, forward 5′-GAAGACCAAGTTCATCTGTGTG-3′, reverse 5′-GGGACATCGGCAGGTCAATGGTAT-3′; IFN-γ, forward 5′-TTCTTCAGCAA CAGCAAGGCGAA-3′, reverse 5′-TGAATGCTTGGCGCTGGACCT G-3′; TNF-α, forward 5′-GATGAGAAGTTCCCAAATGGC-3′, reverse 5′-ACTTGGTGGTTT GCTA CGACG-3′; IL-1β, forward 5′-CAACCAACAAGTGATATTCTCCATG-3′, reverse 5′-GATCCACA CTCTCCAGCTGCA-3′; IL-6, forward 5′-AGACAAAGCC AGAGTCCTTCAGAGA-3′, reverse 5′-TAGCCACTCCTTCTGTGACTCCAGC-3′; CCL2, forward 5′-GCTGTTCACAGTTGCCGGCTG-3′, reverse 5′-GGGCGTTA ACTGCATCTGGCT-3′; CXCL2, forward 5′-ACCAACCACCAGGCTACAG-3′, reverse 5′-GCGTCACACTCAAGCTCT-3′; Cyclin D1, forward 5′-CAAAATGC CAGAGGCGGATG-3′, reverse 5′-CATGGAGGGTGGGTTGGAAA-3′; β-actin, forward 5′-ACCCGCGAGCACAGCTTC TTTG-3′, reverse 5′-CTTTGCACATGCC GGAGCCGTTG-3′.
K-Ras sequencing
The exon 3 of the K-Ras gene was amplified by PCR using AccuPrime Pfx polymerase (Invitrogen, Grand Island, NY, USA) and the following primers: forward 5′-TACAGGAAACAAGTAGTAATTGAT GGAGAA-3′; reverse 5′-ATAAT GGTGAATATCTTCAAATGATTTAGT-3′. The PCR products were then directly used for DNA sequencing. The mutation frequencies of K-Ras in type II lung epithelial cells were determined by the ratios of the area of the mutated nucleotide versus that of WT nucleotide of K-Ras in the sequencing map.
Statistical analysis
Data were reported as mean ± s.d. The Student's t-test (two-tailed) was used to assess significance of differences between two groups, and Pvalues o 0.05 and 0.01 were considered statistically significant and highly statistically significant, respectively. 7, 36 
